To little surprise, Exelixis’ Cotellic — known chemically as cobimetinib — in combination with Roche’s Tecentriq, has failed a late-stage study as a frontline treatment for patients with a form of advanced melanoma.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,